Please upgrade your browser.
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network
Xp11 translocation renal cell carcinoma (RCC) is an RCC subtype affecting 15% of RCC patients <45 years. We analyzed the benefit of targeted therapy [vascular endothelial growth factor receptor (VEGFR)-targeted agents and/or mammalian target of rapamycin (mTOR) inhibitors] in these patients.
Mr Jones asserts that the reduction or elimination of glucose in the diet and taking vitamin B17, together with a strict exercise regime, defeats cancer.
The number of patients required to give a statistically significant result depends on the question the trial wants to answer. For example, to show the effectiveness of a new drug in a non-curable disease as metastatic kidney cancer requires many fewer patients than in a highly curable disease as seminoma if the drug is compared to a placebo.
The company's lead product candidate is currently in last-stage development as a renal cell cancer treatment.
John Baron MP recently met with nurses, clinicians and patient representatives at an event in the House of Lords on 'Improving Outcomes for Kidney Cancer Patients'.
Doctors will today unveil the world's first sticking plaster that can cure cancer.
By observing a laparoscopic radiofrequency ablation procedure live, and seeing first hand the benefits to patients, Sarasota Memorial Urologist Robert Carey, MD, hopes more surgeons will embrace less invasive cancer treatments.
China's demand for Kidney Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow.
Hypoxia-inducible factor (HIF) plays an important role in renal tumourigenesis. In the majority of clear cell RCC (ccRCC), the most frequent and highly vascularized RCC subtype, HIF is constitutively activated by inactivation of the von Hippel-Lindau gene.
|Powered by NeonCRM|